|
Variables
|
No. of studies
|
Test of association
|
Test of heterogeneity
|
|---|
|
HR
|
95% CI
|
P value
|
I2 (%)
|
P value
|
|---|
|
Total
|
35
|
0.578
|
0.522–0.641
|
< 0.001
|
70.10
|
< 0.001
|
|
Publication year
|
|
≤ 2016
|
18
|
0.572
|
0.497–0.660
|
< 0.001
|
67.20
|
< 0.001
|
|
> 2016
|
17
|
0.583
|
0.499–0.681
|
< 0.001
|
72.60
|
< 0.001
|
|
Initial inclusion period
|
|
≤ 2006
|
19
|
0.554
|
0.480–0.640
|
< 0.001
|
72.90
|
< 0.001
|
|
> 2006
|
16
|
0.604
|
0.516–0.707
|
< 0.001
|
68.20
|
< 0.001
|
|
Research region
|
|
Asia
|
28
|
0.584
|
0.520–0.656
|
< 0.001
|
74.90
|
< 0.001
|
|
Europe
|
5
|
0.553
|
0.446–0.685
|
< 0.001
|
0.00
|
0.712
|
|
America and others
|
2
|
0.584
|
0.459–0.744
|
< 0.001
|
0.00
|
0.596
|
|
Number of cases
|
|
< 200
|
19
|
0.632
|
0.547–0.730
|
< 0.001
|
63.20
|
< 0.001
|
|
> 200
|
16
|
0.549
|
0.497–0.606
|
< 0.001
|
41.30
|
0.043
|
|
Median age (years)
|
|
≤ 60
|
13
|
0.585
|
0.496–0.691
|
< 0.001
|
69.20
|
< 0.001
|
|
> 60
|
13
|
0.575
|
0.488–0.679
|
< 0.001
|
75.70
|
< 0.001
|
|
NR
|
9
|
0.557
|
0.427–0.727
|
< 0.001
|
62.60
|
0.006
|
|
Tumor types
|
|
Breast cancer
|
1
|
0.47
|
0.171–1.295
|
0.144
|
–
|
–
|
|
Cervical carcinoma
|
1
|
0.337
|
0.164–0.691
|
0.003
|
–
|
–
|
|
Colon cancer and rectal cancer
|
13
|
0.579
|
0.516–0.650
|
< 0.001
|
0.00
|
0.496
|
|
Ovarian cancer
|
1
|
0.615
|
0.527-0.718
|
< 0.001
|
–
|
–
|
|
Esophageal cancer
|
1
|
0.495
|
0.315– 0.778
|
0.002
|
–
|
–
|
|
Gastric cancer
|
2
|
0.664
|
0.523–0.843
|
0.001
|
0.00
|
0.622
|
|
Head and neck cancer
|
1
|
0.28
|
0.168–0.466
|
< 0.001
|
–
|
–
|
|
Hepatocellular carcinoma
|
1
|
0.73
|
0.399–1.336
|
0.308
|
–
|
–
|
|
Lung cancer
|
5
|
0.594
|
0.435–0.811
|
0.001
|
85.50
|
< 0.001
|
|
Nasopharyngeal carcinoma
|
2
|
0.479
|
0.406–0.566
|
< 0.001
|
0.00
|
0.379
|
|
Pancreatic cancer
|
5
|
0.588
|
0.407–0.851
|
0.005
|
67.90
|
0.014
|
|
Renal cancer
|
2
|
0.827
|
0.755–0.906
|
< 0.001
|
0.00
|
0.7
|
|
LMR cutoff
|
|
< 3.0
|
9
|
0.508
|
0.444–0.582
|
< 0.001
|
16.00
|
0.3
|
|
≥ 3.0
|
26
|
0.612
|
0.546–0.686
|
< 0.001
|
69.80
|
< 0.001
|
|
Therapeutic strategies
|
|
Chemotherapy
|
10
|
0.592
|
0.518–0.676
|
< 0.001
|
31.90
|
0.153
|
|
Molecular targeted
|
2
|
0.622
|
0.304–1.271
|
0.193
|
93.00
|
< 0.001
|
|
Surgery
|
10
|
0.683
|
0.579–0.807
|
< 0.001
|
54.30
|
0.02
|
|
Combined therapy
|
11
|
0.507
|
0.442–0.582
|
< 0.001
|
37.90
|
0.097
|
|
Others
|
2
|
0.563
|
0.400–0.794
|
0.001
|
0.00
|
0.577
|
|
Follow-up period (months)
|
|
≤ 33
|
13
|
0.545
|
0.454–0.653
|
< 0.001
|
67.80
|
< 0.001
|
|
> 33
|
9
|
0.594
|
0.515–0.685
|
< 0.001
|
15.60
|
0.303
|
|
NR
|
13
|
0.606
|
0.504–0.729
|
< 0.001
|
81.10
|
< 0.001
|
|
Quality score
|
|
< 7
|
3
|
0.753
|
0.592–0.958
|
0.021
|
83.20
|
0.003
|
|
≥ 7
|
32
|
0.558
|
0.504–0.619
|
< 0.001
|
58.30
|
< 0.001
|
|
Analysis of hazard ratio
|
|
Multivariate
|
32
|
0.562
|
0.503–0.628
|
< 0.001
|
68.70
|
< 0.001
|
|
Univariate
|
3
|
0.755
|
0.643–0.887
|
0.001
|
23.30
|
0.272
|
- CI confidence interval, HR hazard ratio, No. number, LMR lymphocyte-to-monocyte ratio
